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There is evidence that isolated maternal hypothyroxinemia may have detrimental eﬀects on both mother and foetus. Nonetheless,
thiscondition isstill farfrom being universallyaccepted asa separate thyroid disease,anda standarddeﬁnition ofthisstate ofmild
thyroid underfunction is still lacking. We will review the biochemical criteria used to deﬁne isolated maternal hypothyroxinemia,
together with current methodological issues related to FT4 assays. We will also discuss its epidemiological impact in both iodine-
deﬁcient and-suﬃcient areas, and the eﬀectiveness of iodine prophylaxis on maternal thyroid function and neuropsychomotor
development in oﬀspring.
1.Introduction
The literature of the last few decades provides evidence
that any decrease in thyroid hormone levels during preg-
nancy may be harmful for both mother and foetus [1].
The vast majority of pertinent studies refer to well-
deﬁned clinical presentations of maternal thyroid under-
function, namely, overt hypothyroidism (OH) and sub-
clinical hypothyroidism (SH), both these conditions being
characterized by supra-normal serum TSH levels, with (OH)
orwithout(SH)abnormallylowFT4concentrations.Besides
these forms, a milder presentation of maternal thyroid
underactivity, described as isolated maternal hypothyrox-
inemia, has been reported. This condition, characterized
by low serum FT4 concentrations but normal serum TSH
concentrations, is now recognized as possibly responsi-
ble for adverse maternal and foetal/neonatal outcomes
[2, 3].
This paper aims to discuss some speciﬁc issues related
to isolated hypothyroxinemia, including its epidemiological
impact. In addition, the need to identify and treat early
hypothyroxinemia will be brieﬂy discussed.
2.Isolated MaternalHypothyroxinemia:
Which Isthe CorrectDeﬁnition?
Although almost 40 years have elapsed since Evelyn Man
[4] ﬁrst introduced the concept of hypothyroxinemia being
associated with pregnancy, a precise deﬁnition of this
condition is still lacking.
Analysis of published studies dealing with isolated
hypothyroxinemia reveals that the biochemical criteria on
the basis of which maternal hypothyroxinemia is currently
diagnosed are quite variable (Table 1). In the studies carried
out in the Netherlands by Pop and coworkers, maternal
hypothyroxinemia was deﬁned by FT4 levels below the 10th
percentile and concomitant TSH values <2.0mU/liter [5–
7]. Similarly, Berbel et al. [8] classiﬁed as hypothyroxinemic
those women who were found to have FT4 values below
the 10th percentile. However, TSH concentrations were
considered to be normal up to 4.8mUI/liter, that is to say at
valuesmorethantwicehigherthanthatadoptedintheDutch
studies. In a recent population-based cohort study in the
Netherlands [9],womenwithTSHvalues<2.5mU/literwere
diagnosed as aﬀected by mild and severe hypothyroxinemia2 Journal of Thyroid Research
Table 1: Biochemical criteria used to deﬁne isolated maternal hypothyroxinemia and its epidemiological impact.
Author
(reference number)
(year) country
Lower FT4
percentile
(pmol/liter)
Manufacturer’s
FT4 reference
range (pmol/liter)
Upper TSH limit
(mU/liter)
Manufacturer’s
TSH reference
range (mU/liter)
Prevalence of isolated
hypo-thyroxinemia
(%)
Gestational age of
hypo-thyroxinemia
assessment
Pop et al. [5] (1999)
The Netherlands
10th
(1st tr. 10.4) 8.8–18.0a 2.0 0.15–2.0 NR
Pop et al. [6] (2003)
The Netherlands
10th
(1st tr. 12.4) 8.7–19.6a 2.0 0.15–2.0 NR
Kooistra
et al. [7] (2006)
The Netherlands
10th
(NR) 8.7–19.6a 2.0 0.15–2.0 NR
Casey
et al. [10] (2007)
USA
2.5th
(GW 6-20 11.1) 11.2–24.7b 3.0 NR 1.3% 1st half of gestation
Vaidya
et al. [11] (2007)
UK
2.5th
(1st tr. 10.6) 12.0–23.0c 3.0 0.27–4.2 1.6% (7.8%∗)1 s t t r i m e s t e r
Cleary-Goldman
et al. [13] (2008)
USA
2.5th
(1st tr. 9.3;
2nd tr. 9.3)
10.3–24.4b 1st trim 4.28. 2nd
trim. 3.93 NR 2.1%
2.3%
1st trimester 2nd
trimester
Moleti
et al. [12] (2009)
Italy
2.5th
(1st tr. 11.9;
2nd tr. 10.4;
3rd tr. 10.3)
11.7–22.0d
1st tr. 2.3
2nd tr. 2.8
3rd tr. 3.0
0.4–4.0
3.2%
12.7%
9.5%
1st trimester 2nd
trimester 3rd
trimester
Berbel
et al. [8] (2009)
Spain
10th (10.5) 9.1–23.8e 4.8 0.38–4.8
23.9%
20.6%
26.5%
1st trimester 2nd
trimester 3rd
trimester
Shan
et al. [14] (2009)
China
2.5th
(GW 4 14.1
GW 8 11.9
GW 12 11.4
GW 16 12.3
GW 20 11.6)
10.3–24.5b
GW 4 4.38
GW 8 3.8
GW 12 2.96
GW 16 3.29
GW 20 3.88
0.3–4.8 2.2% (0.4%∗) 1st half of gestation
Henrichs
et al. [9] (2010)
The Netherlands
10th
(11.76)
5th (10.96)
11.0–25.0f 2.5 NR 8.5%( <10th)
4.3%(<5th) GW 13 (median)
∗According to manufacturer’s FT4 reference range; GW: gestational week; NR: not reported.
aEnhanced chemiluminescence immunoassay, Amerlite-MAB (Kodak Clinical Diagnostics, Amersham, UK); bchemiluminescent immunoassay, Immulite
2000 Analyzer (Diagnostic Products Corporation, Los Angeles, CA); celectrochemiluminescent immunoassay, Modular E 170 Analyzer (Roche Diagnostics
Ltd., LewesUK); delectrochemiluminescenceimmunoassay,Modular E 170 Analyzer(Roche Diagnostics GmbH, Mannheim,Germany); echemiluminiscence
immunoassay, ADVIA Centaur-XP immunoassay system (Siemens Medical Solutions Diagnostics Ltd., Llamberis, UK); fenhanced chemiluminescent
immunoassay,Vitros ECI Immunodiagnostic (ORTHO Clinical Diagnostics, Rochester, NY).
based on whether their FT4 concentrations were below the
10th or the 5th percentile, respectively. In the remaining
ﬁve studies listed in Table 1, isolated hypothyroxinemia
is deﬁned by FT4 values below the 2.5th percentile, but
by TSH values ≤3.0mU/liter in two of them [10, 11],
and by values that fall below the upper gestational speciﬁc
limit in the remaining three [12–14]. In particular, Cleary-
Goldman and coworkers identiﬁed an upper limit for TSH
in the 97.5th percentile in a cohort of 10990 women at
both 1st and 2nd trimester, corresponding to 4.28mU/liter
and 3.93mU/liter, respectively [13]. Analogously, Shan et
al. used TSH gestational age reference intervals, calculated
from week 4 up to week 20 of gestation in 120–129
healthy women. The corresponding upper values ranged
2.96–4.38mU/liter, depending on the week of gestation[14].
Finally, a study from our research group referred to TSH
trimester-speciﬁc reference ranges derived from 495 healthy
women at diﬀerent stages of pregnancy. The normal upper
limitswere2.3mU/liter,2.8mU/liter,and3.0mU/liter,at1st,
2nd, and 3rd trimesters, respectively [12].
From the above, it is clear that the criteria for deﬁn-
ing normal levels of FT4 and TSH in pregnant women
are far from homogeneous. This variance has obvious
diagnostic and therapeutic implications. Indeed, depending
on the FT4/TSH threshold considered to be normal, the
same biochemical pattern may be variously deﬁned as
overt/subclinical hypothyroidism, which requires medical
treatment, as isolated hypothyroxinemia, the treatment of
which is advocated by some but not by others, or even as
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3.Are There Normative FT4 and TSH Values to
Deﬁne Isolated MaternalHypothyroxinemia?
Besides the deﬁnitions reported in these studies, Morreale
De Escobar et al. [2] deﬁned hypothyroxinemia to be any
situation characterized by serum FT4 values lower than the
10th percentile value for normal pregnant women with a
conﬁrmed adequate iodine intake at comparable weeks of
gestation, whether or not there is a concomitant increase
in TSH values. Although this deﬁnition combines overt
hypothyroidism and isolated hypothyroxinemia, it is of great
interest as a basis for this discussion in that it emphasizes
the need to refer to gestational-speciﬁc ranges calculated
in properly iodine supplemented women. In the above-
mentioned studies the reference ranges for FT4 and TSH
a r ei ns o m ec a s e st h es a m ea st h o s eu s e df o rt h eg e n e r a l
population, whereas in others they are speciﬁcally calculated
using serum pools from normal pregnant women. The latter
approach is currently regarded as the most appropriate [15]
since pregnancy induces marked changes that invalidate
the nonpregnant reference limits as a means of diagnosing
thyroid dysfunctions in pregnant women. Indeed,during the
1st trimester, the stimulatory eﬀect of hCG on thyrocytes
induces a transient increase in FT4 levels, which is mirrored
by a lowering of TSH concentrations. Following this period,
serum FT4 concentrations decrease slightly (10–15% on
average), and serum TSH values steadily return to normal
[16]. In line with these variations, both FT4 and TSH
reference intervals change throughout pregnancy, depending
on gestational age. Thus, the utilization of nonpregnant
reference intervals to interpret thyroid function tests in
pregnant women carries the risk of misdiagnosis. In a
cross-sectional study, Stricker et al. [17]i nS w i t z e r l a n d
established gestational age-speciﬁc reference ranges for free
and total T3 and T4, and TSH using more than 1800
blood samples obtained from antibody-negative and iodine
suﬃcient women at diﬀerent stages of pregnancy. The
main ﬁnding of this study was that there was a signiﬁcant
diﬀerence between the reference intervals of most thyroid
parameters in the pregnant population and those reported
by the assay manufacturer for nonpregnant subjects. The
authors’ conclusion was that the interpretation of thyroid
function tests in pregnant women using nonpregnant refer-
ence intervals could potentially result in the misclassiﬁcation
of a signiﬁcant percentage of results. It is worth noting
that in that study the lower normal limits for FT4 in the
pregnant population were higher than those reported by the
manufacturer at each interval upto week 30ofgestation,and
only began to decrease at late third trimester. Similarly, in
a series of healthy, antibody-negative, and iodine suﬃcient
women tested in the ﬁrst half of pregnancy, Shan et al. [14]
foundFT4lowerlimitstobeconsistentlyhigherthanthoseof
the nonpregnant population. Accordingly, the prevalence of
isolated hypothyroxinemia in their cohort of 4800 pregnant
women decreased from 2.2% to less than 0.4% based on
whether the gestational or general population reference
ranges were used. Conversely, Vaidya and coworkers [11]
found that the prevalence of hypothyroxinemia was 1.6%
according to their own internal FT4 1st trimester-speciﬁc
reference range, and as high as 7.8% when they used the
manufacturer’s generalpopulationreference range,thelower
FT4 limit in the latter being higher than those found in the
pregnant population (12.0pmol/literversus10.6pmol/liter).
Can the diﬀerent iodine intake account for these diverging
results? Epidemiological data on nutritional iodine status
f r o mt h er e g i o n sw h e r et h et h r e ea f o r e m e n t i o n e ds t u d i e s
were carried out would seem to support this hypothesis. In
2005, Zimmermann et al. [18] reported a median urinary
iodine (UI) concentration of 249µg/liter in a sample of 279
pregnant Swiss women, with almost 80% of them recording
UI levels >140µg/liter. Thus, although nutritional iodine
status was not assessed by Stricker et al. [17], the women
included in their study were reasonably iodine suﬃcient,
a sw e r et h o s ei nt h eC h i n e s es t u d y[ 14], whose median UI
concentration was 180.8µg/liter. Conversely, the available
data suggest that pregnant women in the UK, where the
population is assumed to be iodine replete, might now
be mildly iodine deﬁcient. In particular, a study carried
out in the north east of England has shown that 7%
and 40% pregnant women had UI excretion of less than
50µg/literand 50–100µg/liter, respectively [19]. More recent
ﬁndings seem to conﬁrm comparable data in the south of
England, where median UI concentration in a population
of pregnant women was 98µg/liter [20]. Thus, given the
possible underlying iodine deﬁciency in the population
examined by Vaidya et al. [11], the resulting reference ranges
may not actually reﬂect normal thyroid function, and the
study may consequently have underestimated the prevalence
of isolated hypothyroxinemia.
These considerations underline the importance of refer-
ring to speciﬁc gestational ranges when assessing preg-
nant women’s thyroid function, provided that the women
r e c r u i t e dt od e r i v es u c hr a n g e sh a v ea ni o d i n ei n t a k et h a ti s
k n o w nt ob ea p p r o p r i a t et ot h en e e d so fp r e g n a n c y .
Another problem that deserves attention concerns the
diagnostic accuracy of FT4 testing. Direct analogue FT4
immunoassays currently used to estimate FT4 concentra-
tions are variously biased by either endogenous or in
vitro factors. In particular, these assays are known to be
inﬂuenced to variable degrees by the physiological changes
in thyroxine-binding globulin (TBG) and albumin that
occur during pregnancy [21, 22]. Because of these method-
speciﬁc alterations, the same specimens analyzed by diﬀerent
immunoassay platforms may provide remarkably diﬀerent
results [23]. Conversely, methods of analysis based on the
physical separation of the free from the protein-bound
T4 fraction by equilibrium dialysis (ED) or ultraﬁltration
(UF), before direct quantiﬁcation of the hormone content
in the dialysate/ultraﬁltrate, are generally regarded as ref-
erence methods [24, 25]. However, some theoretical and
technical drawbacks seem to exist even with these methods,
especially with regard to the separation step [26]. Recently,
an International Federation of Clinical Chemistry (IFCC)
working groupproposedFT4measurement byEDcombined
with isotope dilution-liquid chromatography/tandem mass
spectrometry (ED ID-LC/tandem MS) as the reference
measurement procedure (RMP) to measure serum FT4 [27].
In general, most of current routine immunoassays provide4 Journal of Thyroid Research
lower FT4 values than the RMP, even if divergences seem to
be greater for high values rather than for values in the low
range [28, 29]. In a recent study, Anckaert et al. compared
the FT4 results by three diﬀerent immunoassays with those
obtained by an ED ID-LC/tandem MS, with the objective
of verifying the reliability of these assays for monitoring
maternal thyroid function. Interestingly, although all the
tested immunoassays were sensitive to alterations in T4-
binding proteins, two of them gave a FT4 pattern during
pregnancy which was similar to that obtained by ED ID-
LC/tandem MS [30]. In our opinion, the results of this
study are very important from a practical point of view,
since currently the measurement of FT4 by LC/tandem MS
is relatively expensive, technically demanding, and takes too
long to be applied for routine clinical practice.
In summary, measurement of FT4 by isotope dilution
tandem mass spectrometry provides accurate and reliable
results during pregnancy, but these assays are not broadly
available. In contrast, automated immunoassays are cur-
rently the most widely used systems for measuring FT4,
b u tt h e ya r ev a r i o u s l yb i a s e db ys e v e r a lf a c t o r s ,w h i c ha r e
responsible for signiﬁcant method-dependent variations in
FT4 measurement in pregnancy. Because of these method-
ological diﬃculties, establishing normative values of FT4 for
pregnancy is challenging and, whatever the method, it is
recommended that method- and gestation-speciﬁc reference
ranges are used for interpreting results in pregnancy [15, 31].
4.HowCommonIsMaternal
IsolatedHypothyroxinemia?
Deﬁning the true incidenceofisolated maternal hypothyrox-
inemia is rather diﬃcult, especially, but not only, because of
the aforementioned diﬀerences in diagnostic criteria used to
deﬁne the condition. In addition, the epidemiological data
presently available are somewhat sparse.
The issue of the epidemiological impact of isolated
hypothyroxinemia was very recently reviewed by Krassas et
al. [32],who estimated an overall incidenceof approximately
2% in unselected pregnancies. However, it should be noted
that wide diﬀerences exist among the quoted studies, appar-
ently related mainly to iodine nutrition status in the areas
where the studies were conducted. Indeed, in regions where
iodine intake is suﬃcient, as is the case in the United States,
the prevalence of isolated hypothyroxinemia ranges between
1.3%[10]and2.3%[13].Itisworth noting thatalthoughthe
US population is generally iodine suﬃcient, approximately
15% of women of reproductive age have urinary iodine
levels that fall below 50µg/liter, clearly an indication of
iodine deﬁciency [33]. In contrast, in mildly to moderately
iodine deﬁcient regions, isolated hypothyroxinemia aﬀects
a much higher percentage of women, reaching values up
to 25–30% [8, 12]. Interestingly, in a very recent study by
Henrichs et al.[9]carriedoutinTheNetherlandsonacohort
of 3659 women, the prevalence of mild hypothyroxinemia
(FT4 < 10th percentile) was 8.5% and that of severe
hypothyroxinemia(FT4<5thpercentile)4.3%.Theseﬁgures
are signiﬁcantly higher than those reported in previous
studies conducted in iodine suﬃcient regions [10, 13].
The question of when during gestation the diagnosis
of maternal hypothyroxinemia is made is an important
point that deserves attention when attempting an estimate
of the prevalence of this condition. In 2009, we carried
out a longitudinal study of 220 consecutive women from
a mildly iodine-deﬁcient area with the aim of evaluat-
ing the timing of maternal thyroid failure occurrence in
conditions of mild iodine deﬁciency [13]. Although the
overall prevalence of maternal isolated hypothyroxinemia
over the course of gestation was about 25%, analysis of its
frequency distribution revealed that at presentation (<week
12) a comparatively small number of women displayed
FT4 values below the 2.5th percentile for gestational age,
the vast majority dropping to this limit only later in
gestation (12.5% versus 87.5%) (Figure 1). This ﬁnding
indicates that this state of mild thyroid failure tends to
become increasingly frequent as the pregnancy progresses,
and our conclusion was that assessing the prevalence of
isolated hypothyroxinemia on the basis of a single evaluation
during early pregnancy only, has the potential to result in a
substantial underestimation of its true prevalence. Notably,
in our study only a small proportion (7%) of women who
experienced isolated hypothyroxinemia were found to be
antithyroid antibody positive, thus suggesting that features
other than autoimmunity might play a major role in the
occurrenceofthiscondition.Inparticular,wespeculatedthat
isolated hypothyroxinemia might be the result of a failure
of the maternal thyroid to keep up with sustained hormone
demand due to a progressive depletion of iodine stores and
an inadequate daily iodine supply.
5. Is Maternal Isolated Hypothyroxinemia
anIodine DeﬁciencyDisorder?
Although the cause of isolated hypothyroxinemia is not
fully understood, an iodine intake that fails to meet the
requirements of pregnancy may well be responsible. Indeed,
in conditions of mild-moderate iodine deﬁciency, thyroid
stimulation by human chorionic gonadotropin leads to the
preferential output of T3 over T4, the secretion of the
latterbecoming inappropriatelylow relative to the increasing
TBG concentrations. This event leads to the progressive
desaturation of TBG by T4, ultimately resulting in a decline
in FT4 concentrations. Conversely, circulating T3 is normal
(or even slightly over the upper limit) and triggers negative
feedback on pituitary TSH secretion, the concentrations
of which fall within the normal range. As a result, the
women are clinically euthyroid even when biochemically
hypothyroxinemic [2, 34].
The putative pathogenic role of iodine deﬁciency is now
also suggested by clinical studies demonstrating that proper
iodine supplementation during pregnancy reduces the risk
of developing hypothyroxinemia. This point was addressed
by our research group in a longitudinal study aimed at
comparing thyroid function in pregnant women who had
regularly used iodized salt for at least 2 years prior to
becoming pregnant with that of women who began using
iodized salt upon becoming pregnant [35]. The main ﬁndingJournal of Thyroid Research 5
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Figure 1: Frequency distribution of isolated hypothyroxinemia
over the course of gestation in a series of 220 consecutive pregnant
women from a mildly iodine-deﬁcient area (from European Journal
of Endocrinology, by Bioscientiﬁca [12]).
of this study was that short-term iodine prophylaxis did
not protect against the risk of isolated hypothyroxinemia,
the prevalence of which was almost 5-fold higher in short-
termthan inlong-term iodine supplemented women(36.8%
versus 6.4%). Furthermore, in the long-term group isolated
hypothyroxinemia could be detected almost exclusively late
in gestation, thus suggesting that the greater replenishment
of intrathyroidal iodine stores might guarantee an adequate
thyroid hormone output for almost the entire period of
gestation. In 2009, Berbel et al. [8] reported that iodine
supplementationby means of 200µgK Ip e rd a yw a se ﬀective
in restoring euthyroidism (deﬁned as FT4 concentrations
above the 20th percentile) in those women who were found
to be hypothyroxinemic at either weeks 4–6 or 14–16 of
gestation, as well as in maintaining euthyroidism in the
remaining women. Finally, we very recently examined the
eﬀect of diﬀerent levels of nutritional iodine intake on
maternal thyroid function throughout gestation in a cohort
of healthy, antithyroid antibody negative women from a
mildly iodine deﬁcient area. The thyroid function of 168
women who had received prenatal preparations containing
150µg of iodine from early pregnancy was compared with
that of either 105 women who had regularly used (>2yrs)
iodized salt prior to becoming pregnant or 160 women who
had neither taken iodine supplements nor used iodized salt.
The regular use of iodine-containing supplements proved
eﬀective in reducing, though not in completely eliminating,
the risk of inappropriately low FT4 levels during pregnancy,
the overall prevalence of isolated hypothyroxinemia in the
three study groups being 8.3%, 9.5%, and 20%, respectively
[36].
Besides the importance of iodine supplementation
in preventing/correcting maternal hypothyroxinemia, we
would foreground that adequate iodine supply during
pregnancy is essential to providing the foetus with enough
substrate to draw on for its own thyroid hormone synthesis.
The importance ofadequatesupplyofiodine and thyroid
hormone to the developing foetus is emphasized by recent
studies of intervention with iodine and L-thyroxine.
In 2009, Velasco et al. [37]c o m p a r e dt h ec o g n i t i v e
and psychomotor development of 133 infants (aged 3–18
months) born to mothers who had received 300µgo fi o d i n e
from the ﬁrst trimester of pregnancy with that of 61 age-
matched children whose mothers had not received iodine
supplements. The most relevant result of this study is that
the former had a more favourable psychomotor outcome
than those born to mothers who were not treated. Similarly,
Berbel et al. [8] showed that the mean developmental
quotient in children born to mothers supplemented with a
daily dose of 200µg of potassium iodide from 4–6 weeks of
gestation was signiﬁcantly higher than the one recorded for
babiesborntomotherswhohadreceivediodinesupplements
later in gestation. The authors’ conclusion was that a delay of
6–10 weeks in iodine supplementation in hypothyroxinemic
mothers at the beginning of gestation increased the risk of
neurodevelopmental delay in the progeny.
Finally, a large prospective randomized trial of L-T4
treatment in pregnant women with FT4 levels <2.5th centile
and/or TSH >97th centile, the Controlled Antenatal Thyroid
Screening Study (CATS), is presently ongoing. The main
objectives of this study are to evaluate whether abnormal
maternal thyroid function adversely aﬀect neurocognitive
function in oﬀspring and to assess the beneﬁts, if any, of
maternal L-T4 treatment. Preliminary resultsfrom this study
suggest that the mean IQ of children born from treated
mothers is not diﬀerent from that of controls. However,
when the analysis was restricted to children whose mothers
were considered to have been compliant with their L-T4
treatment, a signiﬁcantly higher proportion of children with
IQ < 85 was found in the untreated group [31, 38]. Once
completed, this study will provide important evidence that
should conclusively settle the question of whether or not L-
T4 treatment of maternal isolated hypothyroxinemia is of
beneﬁt in preventing delayed neuropsychological develop-
ment.
6.ConcludingRemarks
There isgrowing evidenceofthepotentialdetrimentaleﬀects
of maternal hypothyroxinemia on both mother and foetus.
In particular, maternal hypothyroxinemia was reported to be
associated with higher risk of placental abruption, preterm
delivery, and increased frequency of Caesarian section [32].
Also, maternal hypothyroxinemia during early gestation
may lead to irreversible brain damage in progeny ranging
over a broad spectrum of neurological phenotypes, from
mentalretardation toneurobehavioralimpairment,aswell as
Attention Deﬁcit and Hyperactivity Disorder, among others
[2,5–9,39].Nevertheless,thisconditionisstillfarfrombeing
universally accepted as a separate thyroid disease. This is
likely the main reason why a standard deﬁnition of this state
of mild thyroid underfunction is still lacking. At present,
the biochemical criteria used to determine whether or not
aw o m a ni sa ﬀected with isolated hypothyroxinemia are in
most cases arbitrarily established. Furthermore, normative6 Journal of Thyroid Research
FT4 gestational ranges appropriately derived from iodine
suﬃcient women are presently lacking [28]. Nor do we
currently know the threshold below which the FT4 values
should be considered potentially harmful to both gestational
outcome and foetal development. Accordingly, there is no
consensus on whether the treatment of women with isolated
hypothyroxinemia with L-Thyroxine is deemed necessary. In
the above mentioned paper by Morreale De Escobar et al., it
issuggestedthatL-Thyroxinetreatment shouldbeprescribed
in women whose free-T4 concentrations fall below the 10th
percentile value, provided that they are also given adequate
iodine supplements [2]. The results of currently ongoing
studies should provide the evidence needed to conclusively
determine whether or not the use of L-T4 in the treatment
of isolated hypothyroxinemia is of beneﬁt in preventing
foetal brain damage [31, 32, 38]. In the meanwhile, we
believethat women found to behypothyroxinemic should be
given substitutive L-thyroxine treatment in order to ensure
FT4 levels that are similar to those observed in adequately
iodine supplemented women at the same stage of pregnancy
[40].
The incidence rates of isolated hypothyroxinemia vary
widely among the studies, due to diﬀerences in either
diagnosticcriteria or inthe timing ofits evaluation,as well as
in the iodine nutrition status of the population under exam-
ination. Overall, the results of more recent studies seem to
indicate that the extent to which isolated hypothyroxinemia
may occur is actually higher than previously estimated, and
likely much higher than that of both subclinical and overt
hypothyroidism. Even more signiﬁcantly, a nonnegligible
prevalence of the condition has been reported in geo-
graphical areas where iodine intake, at least for the general
population, is assumed to be suﬃcient. In the absence of
any evidence of other causes disrupting maternal thyroid
function, the occurrence of isolated hypothyroxinemia in
pregnant women from these areas may be interpreted as the
result of a purely “gestational” iodine deﬁciency, that is to
say an iodine supply that is inadequate to meet the increased
demands of pregnancy.
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